Maiiro founder, Katy Rowe, has announced that the company will be actively supporting research into medical applications of the active ingredients contained in Maiiro’s seaweed based, trademarked formulation, Kelpogen5TM.
"Based on feedback from our customers over the past 18 months, we recognise there is a significant demand and opportunity to enhance the efficacy of our formulations to provide relief and successful treatment of various forms of skin-cancer. We have seen the effects of melanoma and want to help.
We have always known that the seaweed species we use in our products possess exceptionally strong anti-viral and anti-bacterial properties and that is why we chose them in the first place. We know that brown seaweeds such as Fucus Vesiculosis (Bladderwrack) and Undaria Pinnitifida (Wakame) in particular, as used in Kelpogen5, have been studied extensively for their anti-cancer activity since the 1980s. From what we have seen so far, these studies show low side-effects and apparent excellent results in prostrate, bladder, colon, breast and lung cancer.
As a cutting-edge skincare company, we want to be at the forefront of supporting research into skin cancer, with the specific objective of providing a simple, topical, treatment alternative. In 2021, we will be exploring government funding and are in the process of setting up a public funding initiative, along the lines of our 'Pack of Lies' campaign last year, which was very successful in highlighting the damage of plastic pollution on the marine environment."
